COMMUNIQUÉS West-GlobeNewswire

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

25/07/2024 - 22:05

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, announced [...]

Sensus Healthcare to Host Second Quarter 2024 Financial Results and Business Update Conference Call on Thursday, August 8, 2024

25/07/2024 - 22:05

BOCA RATON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological [...]

TELA Bio to Participate in the Canaccord Genuity 44th Annual Growth Conference

25/07/2024 - 22:05

MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the [...]

Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024

25/07/2024 - 22:05

BASEL, Switzerland and LONDON and NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 8, 2024, to [...]

iSpecimen to Report Second Quarter 2024 Results on August 6, 2024

25/07/2024 - 22:05

LEXINGTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a [...]

Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements

25/07/2024 - 22:05

Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company anticipates annualized [...]

Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update

25/07/2024 - 22:05

- Potential best-in-class therapeutic index for lead candidate anti-CTLA-4 SAFEbody ® ADG126 (muzastotug) with higher, more frequent and repeat dosing in combination with Merck’s anti-PD-1 therapy KEYTRUDA* ( [...]

Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update

25/07/2024 - 22:05

NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and [...]

Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

25/07/2024 - 22:00

Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis. 1 This patent strengthens Inventiva’s intellectual property with respect to lanifibranor [...]

Inventiva obtient un nouveau brevet au Japon, élargissant la protection de la propriété intellectuelle de lanifibranor

25/07/2024 - 22:00

► L'Office des brevets japonais a accordé la demande de brevet d'Inventiva concernant l'utilisation de lanifibranor pour le traitement de la cirrhose 1 . ► Ce brevet renforce la propriété intellectuelle d’Inventiva [...]

Cytokinetics to Announce Second Quarter Results on August 8, 2024

25/07/2024 - 22:00

SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 8, 2024 at 4:00 PM Eastern Time. [...]

Canadian Red Cross launches appeal for people affected by Alberta Wildfires

25/07/2024 - 21:43

OTTAWA, July 25, 2024 (GLOBE NEWSWIRE) -- The Canadian Red Cross has launched the 2024 Alberta Wildfires Appeal to help people and communities impacted by wildfires in Alberta. Donations to the Canadian Red Cross will [...]

La Croix-Rouge canadienne lance un fonds de secours pour les personnes touchées par les feux de forêt en Alberta

25/07/2024 - 21:43

OTTAWA, 25 juill. 2024 (GLOBE NEWSWIRE) -- La Croix-Rouge canadienne a mis sur pied le Fonds de secours : Feux de forêt de 2024 en Alberta afin d’aider les personnes et les communautés touchées par les incendies dans la [...]

BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024

25/07/2024 - 19:57

Los Angeles, CA 90025, July 25, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) or (“BioSig” or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac [...]

Full-Body MRI Innovator Ezra and Longhorn Imaging Partner to Bring Full-Body MRI to Central Texas

25/07/2024 - 19:52

Early cancer detection technology now available for the first time for all Central Texas area residents NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Ezra , a healthcare AI startup revolutionizing early cancer detection [...]

Oxurion Share Consolidation

25/07/2024 - 18:00

Oxurion Share Consolidation Leuven, BELGIUM – July 25, 2024 – 06:00 PM CET Oxurion NV (Euronext Brussels: OXUR) (the Company ), a biopharmaceutical company based in Leuven, announced today that its Board of Directors, [...]

EssilorLuxottica: Q2/H1 2024 Results - Sound revenue growth, margins expanding, two acquisitions in line with strategy

25/07/2024 - 18:00

Q2/H1 2024 Results Sound revenue growth, margins expanding, two acquisitions in line with strategy Revenue growing by 5.2% in Q2 at constant exchange rates 1 , +5.3% in H1 EMEA as the driving region, North America [...]

EssilorLuxottica: Résultats T2/S1 2024 - Solide croissance du chiffre d'affaires, amélioration de la marge, deux acquisitions alignées avec la stratégie du Groupe

25/07/2024 - 18:00

Résultats T2/S1 2024 Solide croissance du chiffre d'affaires, amélioration de la marge, deux acquisitions alignées avec la stratégie du Groupe Hausse du chiffre d’affaires du Groupe de 5,2 % au T2 à taux de change [...]

GUERBET : Chiffre d’affaires du 1er semestre 2024.

25/07/2024 - 17:45

Chiffre d’affaires du 1 er semestre 2024 Activité semestrielle Chiffre d’affaires du 1 er semestre : 419,2 M€, en hausse de 11,8% à TCC 1 , intégrant une accélération au 2 ème trimestre (+14,5%) Cette accélération a été [...]